![]() ![]() In the 48-week multicenter, randomized, open-label, 12% noninferiority margin trial, patients with a CD4 nadir of more than 100/L, HIV viral load of less than 50 copies/mL for 12 months or more, and a stable dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) regimen were randomly assigned to continue their regimen or switch to DTG monotherapy.Īccording to Hocqueloux and colleagues, the primary endpoint was the proportion of patients with an HIV viral load of less than 50 copies/mL at week 24 in the intent-to-treat snapshot analysis. ![]() Hocqueloux and colleagues investigated the ability of DTG monotherapy to maintain virologic suppression in people living with HIV on a successful DTG-based triple therapy. Rijnders, MD, PhD, and Casper Rokx, MD, PhD, from the section of infectious diseases at Erasmus University Medical Center in Rotterdam, the Netherlands, noted that when DTG-based combination ART (cART) was approved in the United States in 2013 and in Europe in 2014, evaluating DTG monotherapy as a maintenance treatment strategy “made sense.” However, three prospective clinical trials have showed that DTG monotherapy, while effective in the short term, is “clearly inferior” to cART in the long term, they said. In an editorial also published in Clinical Infectious Diseases, Bart J.A. Our study adds strong evidence for that conclusion,” Hocqueloux told Infectious Disease News. Suppressed people living with HIV because of a significant risk of virological failure with mutation to the class of. “Dolutegravir (DTG) monotherapy is not indicated as a maintenance therapy for long-term Laurent Hocqueloux, MD, from the department of infectious and tropical diseases at the Regional Hospital Center of Orléans in France, and colleagues published results from the MONCAY trial in Clinical Infectious Diseases. Study results showed that dolutegravir monotherapy “is not a valid option” to keep patients with chronic HIV infection virologically suppressed and should not be considered a treatment option, researchers said. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
December 2022
Categories |